← Patent-cliff monitor small molecule DAYVIGO LEMBOREXANT
Loss of exclusivity October 2035 latest FDA-listed patent expiry
Company Eisai → See this company's full patent-cliff portfolio Drug detail Brand name DAYVIGO Active ingredient LEMBOREXANT Strength 10MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval April 2020 Marketing status RX
Listed patents Patent Expires Type 10188652 October 2035 product 10702529 October 2035 product 11026944 October 2035 product 8268848 September 2031 substance, product
Regulatory exclusivity Code Expires M-293 April 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.